We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Strikes $78M Deal In Elan Abraxane IP Suit

Law360 (February 24, 2011, 10:18 PM EST) -- Elan Pharma International Ltd. and Celgene Corp. announced a $78 million settlement Thursday that ends four years of litigation over breast cancer drug Abraxane, which allegedly infringed two patents held by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.